GERMANTOWN, Md., Feb. 3, 2015 /PRNewswire/ -- Neuralstem,
Inc. (NYSE MKT: CUR) announced that Richard
Garr, President and CEO, will present at the 17th
Annual BIO CEO & Investor Conference on Monday, February 9, at 3:30 p.m. EST at the Waldorf Astoria in
New York City.
A live audio webcast of the presentation will be available by
visiting the Investor Center home page of Neuralstem's website:
investor.neuralstem.com. An archive of the presentation will be
available for 30 days.
About Neuralstem
Neuralstem is a dual platform regenerative medicine company. The
company's technology enables the production of regionally specific,
physiologically relevant neural stem cells for therapeutic use for
the treatment of central nervous system (CNS) diseases and has
enabled the discovery of a library of patented small molecule
neurogenic compounds to treat psychological and cognitive
disorders.
Neuralstem's small molecule drug discovery program screens human
neural stem cell lines for compounds that may stimulate
neurogenesis in the brain, possibly reversing pathologies
associated with certain CNS conditions. The company's lead
compound, NSI-189, has completed FDA Phase Ia and Ib safety trials
for the treatment of major depressive disorder (MDD). Neuralstem is
expecting to launch a Phase II study for MDD in 2015.
Neuralstem's first stem cell therapy product, NSI-566, a spinal
cord-derived neural stem cell line, is in ongoing clinical trials
to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease), for which it has received
orphan status designation by the FDA. Dosing in a phase IIa trial
was completed in July, 2014. The next trial is anticipated to
commence in 2015. In addition to ALS, the company is conducting an
NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566
clinical development also underway to treat ischemic stroke.
For more information, please visit www.neuralstem.com or connect
with us on Twitter, Facebook and LinkedIn
Cautionary Statement Regarding Forward Looking Information:
This news release may contain forward-looking statements made
pursuant to the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Investors are cautioned that such
forward-looking statements in this press release regarding
potential applications of Neuralstem's technologies constitute
forward-looking statements that involve risks and uncertainties,
including, without limitation, risks inherent in the development
and commercialization of potential products, uncertainty of
clinical trial results or regulatory approvals or clearances, need
for future capital, dependence upon collaborators and maintenance
of our intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed
from time to time in Neuralstem's periodic reports, including the
annual report on Form 10-K for the year ended December 31, 2013 and Form 10Q, for the period
ended September 30, 2014.
Logo -
http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/neuralstem-to-present-at-bio-ceo--investor-conference-2015-300029585.html
SOURCE Neuralstem, Inc.